Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: A cross-sectional study

Alzheimer's Research and Therapy

Volumn 4, Issue 6, 2012, Pages

  Davidson, Julie E ^a,b   Lockhart, Andrew ^c   Amos, Leslie ^d   Stirnadel Farrant, Heide A ^a   Mooser, Vincent ^d   Sollberger, Marc ^b   Regeniter, Axel ^b   Monsch, Andreas U ^b   Irizarry, Michael C ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; GENOTYPE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL;

EID: 84870500488     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt154     Document Type: Article

References (31)

1. 2 and cardiovascular diseases. Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Sacco R, Elkind M, Talmud P, Rimm E, Cannon CP, Packard C, et al. Eur J Cardiovasc Prev Rehabil 2007 14 3 11 17301621
2. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F, Mayo Clin Proc 2007 82 159 165 17290721 (Pubitemid 46198473)
3. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J, Lancet 2010 375 1536 1544 20435228
4. Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Purnell C, Gao S, Callahan CM, Hendrie HC, Alzheimer Dis Assoc Disord 2009 23 1 10 10.1097/WAD.0b013e318187541c 18703981
5. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. van Oijen M, van der Meer IM, Hofman A, Witteman JC, Koudstaal PJ, Breteler MM, Ann Neurol 2006 59 139 144 10.1002/ana.20721 16278861 (Pubitemid 43042880)
6. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. van Himbergen TM, Beiser AS, Ai M, Seshadri S, Otokozawa S, Au R, Thongtang N, Wolf PA, Schaefer EJ, Arch Neurol 2012 69 594 600 10.1001/archneurol.2011.670 22213409
7. Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Drenos F, Talmud PJ, Casas JP, Smeeth L, Palmen J, Humphries SE, Hingorani AD, Hum Mol Genet 2009 18 2305 2316 10.1093/hmg/ddp159 19336475
8. 2G7 V297F null mutation) and risk of Alzheimer's disease in Japan. Koshy B, Miyashita A, St Jean P, Stirnadel H, Kaise T, Rubio JP, Mooser V, Kuwano R, Irizarry MC, J Alzheimers Dis 2010 21 775 780 20634581
9. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 10.1212/WNL.34.7.939 6610841 (Pubitemid 14076461)
10. Current concepts in mild cognitive impairment. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B, Arch Neurol 2001 58 1985 1992 10.1001/archneur.58.12.1985 11735772 (Pubitemid 33143977)
11. Impact of APOE status on cognitive maintenance in healthy elderly persons. Zehnder AE, Blasi S, Berres M, Monsch AU, Stahelin HB, Spiegel R, Int J Geriatr Psychiatry 2009 24 132 141 10.1002/gps.2080 18615849
12. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER III, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A, for the Darapladib Investigators, J Am Coll Cardiol 2008 51 1632 1641 10.1016/j.jacc.2007.11.079 18436114 (Pubitemid 351635837)
13. Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. Schnabel R, Dupuis J, Larson MG, Lunetta KL, Robins SJ, Zhu Y, Rong J, Yin X, Stirnadel HA, Nelson JJ, Wilson PWF, Keaney JF, Vasan RS, Benjamin EJ, Atherosclerosis 2009 204 601 607 10.1016/j.atherosclerosis.2008.10.030 19135199
14. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Witheimsen L, Graham IM, Eur Heart J 2003 24 987 1003 10.1016/S0195-668X(03)00114-3 12788299 (Pubitemid 36712275)
15. Cerebral blood flow in dementia. Hachinski VC, Iliff LD, Zilhka E, Arch Neurol 1975 32 632 637 10.1001/archneur.1975.00490510088009 1164215
16. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J, J Neurol Sci 1993 114 7 12 10.1016/0022-510X(93)90041-V 8433101 (Pubitemid 23025201)
17. A new rating scale for age-related white matter changes applicable to MRI and CT. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P, Stroke 2001 32 1318 1322 10.1161/01.STR.32.6.1318 11387493 (Pubitemid 32530416)
18. Alzheimer's disease. Cummings JL, New Engl J Med 2004 351 56 67 10.1056/NEJMra040223 15229308 (Pubitemid 38857248)
19. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, de Lemos JA, Atherosclerosis 2008 199 110 115 10.1016/j.atherosclerosis.2007.10.010 18061193 (Pubitemid 351842698)
20. 2 and cardiovascular diseases. Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Meisinger C, Sacco R, Elkind M, Talmud P, Rimm E, Cannon CP, et al. Eur J Cardiovasc Prev Rehabil 2007 14 3 11 17301621
21. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. Stafforini DM, Tjoelker LW, McCormick SPA, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM, J Biol Chem 1999 274 7018 7024 10.1074/jbc.274.11.7018 10066756 (Pubitemid 29140510)
22. Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality. Heart Protection Collaborative Group, J Intern Med 2010 268 348 358 21050287
23. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. Folstein MF, Folstein SE, McHugh PR, J Psychiatr Res 1975 12 189 198 10.1016/0022-3956(75)90026-6 1202204
24. Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Drenos F, Talmud PJ, Casas JP, Smeeth L, Palmen J, Humphries SE, Hingorani AD, Hum Mol Genet 2009 18 2305 2316 10.1093/hmg/ddp159 19336475
25. 2 activity and mass in the framingham heart study. Suchindran S, Rivedal D, Guyton JR, Milledge T, Gao X, Benjamin A, Rowell J, Ginsburg GS, McCarthy JJ, PLoS Genet 2010 6 1000928 10.1371/journal.pgen.1000928 20442857
26. Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men. El Saed A, Sekikawa A, Zaky RW, Kadowaki T, Takamiya T, Okamura T, Edmundowicz D, Kita Y, Kuller LH, Ueshima H, J Epidemiol 2007 17 179 185 10.2188/jea.17.179 18094516
27. The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. Allison MA, Denenberg JO, Nelson JJ, Natarajan L, Criqui MH, J Vasc Surg 2007 46 500 506 10.1016/j.jvs.2007.04.038 17681710 (Pubitemid 47361606)
28. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Hampel H, Bürger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K, Alzheimer's Dementia 2008 4 38 48 10.1016/j.jalz.2007.08.006 23239205
29. Biomarkers of Alzheimer disease in plasma. Irizarry MC, NeuroRx 2004 1 226 234 10.1602/neurorx.1.2.226 15717023 (Pubitemid 46591884)
30. Determination of a specific lipoprotein-associated phospholipase A2 activity in human cerebrospinal fluid. Ye L, Li T, Lee D, Huang C, Guan C, Amos L, Sollberger M, Regeniter A, Monsch AU, Irizarry MC, Lockhart A, Alzheimer's Dementia 2010 6 500 23239205
31. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. Blennow K, NeuroRx 2004 1 213 225 10.1602/neurorx.1.2.213 15717022 (Pubitemid 46589353)